Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial hypertension experienced a 76% reduction in the composite risk of death, ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in patients with relapsed or refractory multiple myeloma treated with ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is supporting cancer care teams through timely education, community-based trials, ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and ...

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

What’s impacting medical affairs today is the update to drug approvals: there’s more visibility, more scrutiny, and more complexity. The number one issue is the lack of good corporate governance.

Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis. Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis. 1 The companies will ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among Americans, and these medications provided many with a healthy way to drop the ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is reshaping life sciences investments through a combination of uncertainty in ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of quantitative PET imaging metrics to support diagnosis and monitor disease ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant improvements in both progression-free survival and objective response rate in ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and ...